Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
Background Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and $ CD8^{+} $ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. Materials and methods We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. Results We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. Conclusions Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Cancer immunology immunotherapy - 70(2021), 11 vom: 10. Apr., Seite 3277-3289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arranz-Nicolás, Javier [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Combination |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s00262-021-02924-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045266190 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045266190 | ||
| 003 | DE-627 | ||
| 005 | 20230519160157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211012s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-021-02924-5 |2 doi | |
| 035 | |a (DE-627)SPR045266190 | ||
| 035 | |a (SPR)s00262-021-02924-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.81 |2 bkl | ||
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Arranz-Nicolás, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
| 520 | |a Background Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and $ CD8^{+} $ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. Materials and methods We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. Results We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. Conclusions Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer. | ||
| 650 | 4 | |a T Lymphocytes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug Therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Combination |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Programmed Cell Death-1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diacylglycerol Kinase |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Martin-Salgado, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Adán-Barrientos, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Liébana, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a del Carmen Moreno-Ortíz, María |e verfasserin |4 aut | |
| 700 | 1 | |a Leitner, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Steinberger, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ávila-Flores, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Merida, Isabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Berlin : Springer, 1976 |g 70(2021), 11 vom: 10. Apr., Seite 3277-3289 |w (DE-627)SPR003214370 |w (DE-600)1458489-X |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:11 |g day:10 |g month:04 |g pages:3277-3289 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00262-021-02924-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.81 |q ASE |
| 936 | b | k | |a 44.45 |q ASE |
| 951 | |a AR | ||
| 952 | |d 70 |j 2021 |e 11 |b 10 |c 04 |h 3277-3289 | ||